RVL Pharma Issues Interim Q2 Sales From Its Droopy Eye Treatment
February 2, 2024
CNBC
RVL Pharmaceuticals plc (NASDAQ: RVLP ) announced preliminary Q2 FY22 sales from Upneeq of $8.4 million , up 42% sequentially.
Upneeq (oxymetazoline hydrochloride ophthalmic solution) is an approved ophthalmic solution for blepharoptosis or droopy eyelids.
The company also announced that from ... Full story available on Benzinga.com
SweepCast
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.